5414002026-01-012026-03-315414002026-03-315414002025-03-315414002025-04-012026-03-315414002026-01-012026-03-31in-capmkt:OtherExpenses1Member5414002025-04-012026-03-31in-capmkt:OtherExpenses1Member5414002026-03-31OtherNoncurrentFinancialAssetsDomain15414002026-03-31OtherNoncurrentFinancialAssetsDomain25414002026-03-31OtherCurrentFinancialAssetsDomain15414002026-03-31OtherCurrentAssetsDomain15414002026-03-31OtherNoncurrentFinancialLiabilitiesDomain15414002026-03-31OtherCurrentFinancialLiabilitiesDomain15414002026-03-31OtherCurrentFinancialLiabilitiesDomain25414002026-03-31OtherCurrentLiabilitiesDomain15414002026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15414002025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15414002026-01-012026-03-31RelatedPartyTransactionDomain15414002025-12-31RelatedPartyTransactionDomain15414002026-03-31RelatedPartyTransactionDomain15414002026-01-012026-03-31RelatedPartyTransactionDomain25414002025-12-31RelatedPartyTransactionDomain25414002026-03-31RelatedPartyTransactionDomain25414002026-01-012026-03-31RelatedPartyTransactionDomain35414002025-12-31RelatedPartyTransactionDomain35414002026-03-31RelatedPartyTransactionDomain35414002026-01-012026-03-31RelatedPartyTransactionDomain45414002025-12-31RelatedPartyTransactionDomain45414002026-03-31RelatedPartyTransactionDomain45414002026-01-012026-03-31RelatedPartyTransactionDomain55414002025-12-31RelatedPartyTransactionDomain55414002026-03-31RelatedPartyTransactionDomain55414002026-01-012026-03-31RelatedPartyTransactionDomain65414002025-12-31RelatedPartyTransactionDomain65414002026-03-31RelatedPartyTransactionDomain65414002026-01-012026-03-31RelatedPartyTransactionDomain75414002025-12-31RelatedPartyTransactionDomain75414002026-03-31RelatedPartyTransactionDomain75414002026-01-012026-03-31RelatedPartyTransactionDomain85414002025-12-31RelatedPartyTransactionDomain85414002026-03-31RelatedPartyTransactionDomain85414002026-01-012026-03-31RelatedPartyTransactionDomain95414002025-12-31RelatedPartyTransactionDomain95414002026-03-31RelatedPartyTransactionDomain95414002026-01-012026-03-31RelatedPartyTransactionDomain105414002025-12-31RelatedPartyTransactionDomain105414002026-03-31RelatedPartyTransactionDomain105414002026-01-012026-03-31RelatedPartyTransactionDomain115414002025-12-31RelatedPartyTransactionDomain115414002026-03-31RelatedPartyTransactionDomain115414002026-01-012026-03-31RelatedPartyTransactionDomain125414002025-12-31RelatedPartyTransactionDomain125414002026-03-31RelatedPartyTransactionDomain125414002026-01-012026-03-31RelatedPartyTransactionDomain135414002025-12-31RelatedPartyTransactionDomain135414002026-03-31RelatedPartyTransactionDomain135414002026-01-012026-03-31AuditorDomain15414002026-03-31Statement15414002026-01-012026-03-31Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares541400ZIMLABNOTLISTEDINE518E01015ZIM Laboratories LimitedMain BoardEquity2025-04-012026-03-312026-05-192026-05-12INRLakhsQuarterlyFourth quarterSingle segmentPharmacuetical2026-05-1912:45:002026-05-1916:30:00trueCash Flow IndirectDeclaration of unmodified opiniontruetrueNANAfalsetrue2025-02-10www.zimlab.intrue1falseThe Company has not made any defults on payment of Loans and Debts Securities during the period under review.2026-01-012026-03-31UnauditedStandalone102853700061586000109012300048846600023596000-51213000162783000331030004900700033912700010448690004525400004525400018083000-565000012433000032821000000032821000305600035877000535003000100.670.67000.670.670.00430.01260.0237Notes : <BR> <BR> 1) The above statement of standalone financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 18 May 2026 and 19 May 2026. There are no qualifications in the audit report issued for the year ended 31 March 2026. <BR> <BR> 2) These financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard ('Ind AS') notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended), as prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations and guidelines issued by the Securities and Exchange Board of India (SEBI). <BR> <BR> 3) The standalone financial results of the Company for the quarter and year ended 31 March 2025 were reviewed/audited by another auditor, who expressed an unmodified conclusion/opinion on those results on 20 May 2025 <BR> <BR> 4) The figures for the quarters ended 31 March 2026 and 31 March 2025 are the balancing figures between the audited figures for the years ended as on that date and the year to date figures upto the end of third quarter of the respective financial years, on which auditors had performed a limited review. <BR> <BR> 5) The Company is principally engaged in a single business segment which is "pharmaceuticals". There is no separate reportable segment as per Ind AS 108 - Operating Segments. <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> Place: Nagpur Anwar S. Daud <BR> Date: 19 May 2026 Managing Director2025-04-012026-03-31AuditedStandalone37048150001138990003818714000163190500074683000-61414000600985000132023000193674000116285600037347120008400200008400200032754000-840400024350000059652000000059652000-982000586700005350030001023285180001.221.22001.221.220.00430.01110.0164Other Expenses339127000Other Expenses1162856000156373800058760200000375310003064360000017655600000558210002323770000272768400093774800009228360001879570001820080000487200012976730002888920002524313000005251997000535003000232851800028635210002863521000415883000000832000042420300001042030000528406000813956000847200006811220007658420001217940001701592000124121000859400025763000018600700000023884760005251997000Deferred tax asset (Net)0Other Non current asset55821000Other current financial assets4872000Other current assets288892000Lease Liabilities8320000Other current financial liabilities94364000Lease Liabilities27430000Other current liabilities124121000132023000-7304800046231000002128000-420000576890000411200000077919000193674000000-650000-284090007500030920003303000000-18106000-2320000042855200051255400000035970000047658400003812000000000056165000416287000000000000000000007500015810000-177532000-5741180000035000000000077600002483650001465350003938800001289500000-2412000281856000184322000-10001843210003636000187957000Measurements of defined employee benefit plans43120004312000Measurements of defined employee benefit plans-1385000-13850001256000-403000003056000-982000ZIM Laboratories Limited******Dr. Anwar S. Daud******Managing Director and shareholder with significant influenceRemunerationApproved8071000828000802000ZIM Laboratories Limited******Dr. Anwar S. Daud******Managing Director and shareholder with significant influenceAny other transactionRent ReceivedApproved1463000658000616000ZIM Laboratories Limited******Mr. Zulfiquar Kamal******Director (Finance)RemunerationApproved5594000505000574000ZIM Laboratories Limited FZE, UAE (Wholly-Owned Subsidiary)******Mr. Zulfiquar Kamal******Director (Finance)RemunerationApproved1486000242000258000ZIM Laboratories Limited******Pachira Financial Services LLP******Related Party of wholly owned Subsidiary - ZIM Health Technologies LimitedPurchase of goods or servicesApproved4000000375000120000ZIM Laboratories Limited******ZIM Laboratories Limited FZE (Wholly-Owned Subsidiary******Wholly owned subsidiarySale of goods or servicesApproved198542000429000-60277000ZIM Laboratories Limited******ZIM Laboratories Limited FZE (Wholly-Owned Subsidiary******Wholly owned subsidiarySale of goods or servicesApproved465900004659000ZIM Laboratories Limited******ZIM Health Technologies Limited, India******Wholly owned subsidiaryPurchase of goods or servicesApproved195720003045000038107000ZIM Laboratories Limited******ZIM Health Technologies Limited, India******Wholly owned subsidiaryAny other transactionDeemed InvestmentApproved39770001366900017646000ZIM Laboratories Limited******ZIMTAS PTY Limited******Subsidiary CompanyInvestmentApproved8945000736200016307000ZIM Laboratories Limited FZE, UAE (Wholly-Owned Subsidiary)******ZIM SCIENTIFIC OFFICE LLC******Wholly owned subsidiary of ZIM Laboratories Limited FZE, UAESale of goods or servicesApproved915100000ZIM Laboratories Limited******Dr. Chandra-shekhar Mainde******Executive Director and Chief Executive Officer (Wholly owned subsidiary)Any other transactionRent PaidApproved1260000216000238000ZIM Laboratories Limited******Mr. Girdhar Balwani******Related Party of Subsidiary - ZIMTAS PTY LimitedPurchase of goods or servicesApproved86200000267582000AuditedtrueDelloite Hasinks & Sells LLPtrue2027-07-31Preferential Issues2026-03-13349999949620002026-03-31falsefalseDr. Anwar DaudManaging DirectorNagpur2026-05-16